- The China Food and Drug Administration halts the sale of Tianyin Pharmaceuticals' (TPI +3.1%) liver drug Hugan as it performs due diligence on its price and GMP before awarding the firm the right to sell the product in Zhejiang province. The agency's action is a customary part of its regulatory process.
- The product contributes ~$600K in annual sales.
- The company expects the examination to be over in April and sales will recommence.
at Benzinga.com (Jan 2, 2015)